EU and US could reach trade deal this weekend - Reuters
In a significant legal development, Walgreens Boots Alliance, Inc. (NASDAQ:WBA), a $9.42 billion market cap company with annual revenues of $151.95 billion, has reached a settlement with the Department of Justice (DOJ) over allegations related to the dispensing of opioids and other controlled substances. According to InvestingPro data, the company currently maintains a concerning financial health score of 1.62 (Weak), adding context to its legal challenges. The agreement, announced today, concludes a series of litigations involving the retail pharmacy giant and federal agencies.
The settlement, which involves no admission of wrongdoing or liability by Walgreens, requires the company to pay $300 million plus interest, accruing at an annual rate of 4.0%, over a six-year period. An initial payment of $20 million plus interest is due within 21 days of the settlement execution. With a total debt of $31.1 billion and a debt-to-equity ratio of 4.38, this settlement adds to the company’s financial obligations. Additionally, a contingency payment of up to $50 million could be triggered if Walgreens meets specific future free cash flow targets or if certain corporate transactions occur during the settlement term.
This arrangement stems from a lawsuit filed by Walgreens in January 2025 against the DOJ and the U.S. Drug Enforcement Administration (DEA), seeking declaratory judgment related to the enforcement of certain rules by the DEA. The DOJ subsequently filed a counter lawsuit against Walgreens in the Northern District of Illinois, alleging violations of the Controlled Substance Act and other laws.
The settlement agreement, which also involves the dismissal of all claims against Walgreens and the DEA in both courts, is seen as the last major anticipated opioid regulatory matter for the company. It is intended to mitigate the cost and uncertainty of continued litigation.
Walgreens, a Delaware-incorporated company with headquarters in Deerfield, Illinois, is listed on The Nasdaq Stock Market LLC under the ticker symbol WBA. Currently trading at $10.89, the stock offers a notable dividend yield of 9.18%. InvestingPro analysis indicates the stock is currently fairly valued, with additional insights available in the comprehensive Pro Research Report, part of InvestingPro’s coverage of over 1,400 US stocks. The company’s legal and financial maneuver through this settlement is expected to resolve its ongoing opioid-related legal challenges.
Investors and the public are cautioned that this report contains forward-looking statements subject to risks, uncertainties, and assumptions as described in the company’s SEC filings. Walgreens has stated it does not plan to update any forward-looking statements following this release.
This news is based on a press release statement and reflects the latest information available as of April 18, 2025.
In other recent news, Walgreens Boots Alliance has announced an agreement to be acquired by Sycamore Partners, with the transaction valued at up to $23.7 billion. This deal offers Walgreens shareholders $11.45 per share in cash, with the potential for an additional $3 per share from future sales of VillageMD assets. The acquisition is expected to close in the fourth quarter of 2025, pending regulatory and shareholder approvals. Analysts have weighed in on the developments, with Jefferies raising Walgreens’ stock target to $11.45, maintaining a Hold rating, while UBS also increased its target to $11.45 and kept a Neutral rating. Deutsche Bank (ETR:DBKGn), however, downgraded the stock to Sell, citing concerns over the complexity of the deal and potential undervaluation. Raymond (NSE:RYMD) James continues to rate Walgreens at Market Perform, expressing skepticism about the expected earnings boost from the transaction. The "go-shop" period allows Walgreens to explore alternative offers, although the likelihood of a superior bid remains uncertain. Walgreens is also set to release its fiscal 2025 second quarter earnings on April 8, 2025, without a conference call.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.